Steris (FRA:2TG) NonCurrent Deferred Liabilities: €338 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:2TG Steris PLC FRA:2TG
83 GF Score
Price €189.70
GF Value €233.49
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Steris NonCurrent Deferred Liabilities?

Steris FRA:2TG +8.09% 83 NonCurrent Deferred Liabilities is €338 Mil as of Mar. 2026. GuruFocus rates FRA:2TG with a GF Score™ of 83/100 and a GF Value™ of €233.49 (Modestly Undervalued). The stock has 1 warning sign investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Steris's non-current deferred liabilities for the quarter that ended in Mar. 2026 was €338 Mil.

Steris NonCurrent Deferred Liabilities Related Terms

Steris NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Steris's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Steris NonCurrent Deferred Liabilities Chart

Steris Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 708.80 576.78 441.31 373.42 337.96

Steris Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 373.42 356.68 351.02 353.98 337.96
FRA:2TG
83GF Score
Steris PLC FRA:2TG
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of €338 Mil mean?
Steris (FRA:2TG) has a NonCurrent Deferred Liabilities of €338 Mil as of Mar. 2026. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Steris and its competitors.
Is Steris' NonCurrent Deferred Liabilities too high?
Steris' current NonCurrent Deferred Liabilities is €338 Mil. Overall, Steris has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Steris' NonCurrent Deferred Liabilities compare to ZBH and DXCM?
Steris' NonCurrent Deferred Liabilities of €338 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Medical Devices & Instruments company?
A good NonCurrent Deferred Liabilities depends on the Medical Devices & Instruments industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Steris and its competitors. Steris's current NonCurrent Deferred Liabilities is €338 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Steris stock overvalued right now?
Based on GuruFocus' analysis, Steris (FRA:2TG) is currently considered Modestly Undervalued. The stock's GF Value™ is €233.49, compared to a current price of €189.70 — trading 18.8% below its estimated fair value. The current NonCurrent Deferred Liabilities is €338 Mil. Steris' overall GF Score™ is 83/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Steris (FRA:2TG), the current NonCurrent Deferred Liabilities is €338 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Steris (FRA:2TG) Overvalued in 2026?

Based on GuruFocus' analysis, Steris stock appears to be undervalued. The current stock price of €189.70 is trading 18.8% below its estimated GF Value™ of €233.49. GuruFocus considers Steris to be Modestly Undervalued.

Key valuation signals for FRA:2TG:

  • NonCurrent Deferred Liabilities: €338 Mil
  • GF Value™: €233.49 vs. price of €189.70 (18.8% below fair value)
  • GF Score™: 83/100 with 1 warning sign

No single metric tells the full story. See the FRA:2TG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Steris Business Description

Other Exchanges STE:USAS1TE34:Brazil
Address 70 Sir John Rogerson\'s Quay, Dublin, IRL, D02 R296
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Steris also sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 20% from Applied Sterilization Technologies, or AST, and 10% from life sciences services after the divestment of its dental products business.
83GF Score

Get the complete analysis for FRA:2TG

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€189.70
Price
€233.49
GF Value